On April 25, 2024, the FDA made a pivotal decision by approving the first over-the-counter continuous glucose monitor (CGM), the Dexcom Stelo Glucose Biosensor System. This move signals a transformative change in diabetes care for millions of Americans. For the first time, individuals aged 18 and older living with Type 2 diabetes or prediabetes can access CGMs without a prescription. The device is expected to become available by summer 2024.
The Dexcom Stelo system represents a major advancement for people who have traditionally lacked access to continuous monitoring tools. Previously, non-insulin-dependent patients monitored their blood sugar using fingerstick tests—a cumbersome method that provides only intermittent readings. This new device allows them to track their glucose levels continuously, offering a more comprehensive view of their health.
“This is the first step in a broader effort to expand access to CGMs in populations that haven’t been able to use them,” stated Dexcom Chief Operating Officer Jake Leach. He emphasized that the removal of the prescription requirement eliminates a significant barrier to care, enhancing diabetes management options for many.
How It Works
The Stelo system consists of a wearable sensor and a mobile app. The sensor, applied to the skin, continuously measures glucose levels in the interstitial fluid just beneath the skin’s surface, and it needs replacement every 15 days. The sensor syncs with a smartphone app that displays real-time data on glucose levels, trends, and alerts for abnormal levels—allowing users to manage their health without frequent fingerstick tests.
The FDA confirmed the safety and effectiveness of the Stelo system through clinical studies and real-world data. The simplified setup process lends itself to increased self-management, catering to the rising number of Americans living with diabetes.
Why It Matters
Diabetes is a pressing health concern in the United States, affecting approximately 38 million people, with about 90 to 95 percent diagnosed with Type 2 diabetes. Most of these individuals are not insulin-dependent, resulting in limited access to CGMs until now. An additional 96 million adults are categorized as prediabetic.
Wider access to CGMs offers benefits that extend beyond individual patients. Continuous glucose tracking empowers users to better manage their diet, exercise, and medication. Research indicates that CGM usage among non-insulin-dependent individuals can lead to enhanced glycemic control and lower risks for serious complications like heart disease and kidney damage.
Economic and Access Implications
Historically, stringent prescription requirements and insurance coverage have hindered CGM adoption. Insurance companies commonly cover CGMs only for insulin-dependent patients. The retail availability of Dexcom’s Stelo may circumvent these insurance issues, though pricing details are yet to be confirmed. Dexcom aims to set an affordable price point to ensure widespread availability in pharmacies and online.
This OTC approval is particularly significant for rural and underserved populations who face unique challenges in accessing diabetes care. Many patients in these areas lack easy access to endocrinologists or primary care physicians who can prescribe CGMs. The availability of an OTC device allows these individuals to take charge of their health, regardless of healthcare system limitations.
FDA Oversight and Future Trends
The FDA authorized the Stelo system under its de novo pathway, which addresses novel medical devices without existing equivalents. The agency’s evaluation included performance data from clinical trials involving users who do not require insulin and are not at high risk of hypoglycemia, confirming that the device is appropriate for its intended audience.
It’s important to note that this approval is not applicable to individuals with Type 1 diabetes or those on insulin therapy, as the device does not interface with insulin pumps or automatic delivery systems. Nonetheless, the trend of expanding CGM access could continue, with other manufacturers like Abbott Laboratories set to launch their own OTC glucose sensor later this year.
Current projections estimate the U.S. CGM market, valued at $6.2 billion in 2023, will grow significantly over the next decade. The introduction of OTC devices could greatly accelerate this growth by reaching an underserved population of Type 2 diabetics.
Public Health Impact
A recent study from 2022 highlighted that individuals with non-insulin-treated Type 2 diabetes using CGMs exhibited greater engagement in health management, better dietary decisions, and improved control over blood sugar levels. Furthermore, noticing blood sugar patterns early can help those with prediabetes avert progression to Type 2 diabetes.
“Patients want to feel empowered in their care, and real-time data gives them that power,” noted Dr. Kelly Close, founder of the diaTribe Foundation. “This is a lifeline for so many people who have been underserved by healthcare access and insurance red tape.”
According to CDC estimates, diabetes costs the U.S. around $327 billion annually due to medical expenses and lost productivity. Increased CGM usage could mitigate these costs by preventing complications and reducing hospital visits.
Conclusion
The FDA’s landmark approval of the first OTC continuous glucose monitor holds the potential to redefine diabetes care in America. Millions of individuals affected by Type 2 diabetes can soon monitor their health continuously and independently. If adopted widely, this advancement could diminish healthcare disparities, enhance health outcomes, and lessen significant long-term complications.
As competition heats up and more OTC options emerge, access may broaden, and prices may decrease, giving patients navigating chronic illness a chance at better health management. This approval paves the way for a more autonomous approach to managing diabetes, enhancing quality of life for countless individuals.
"*" indicates required fields